7-溴-3-苯基喹啉-2(1H)-酮 | 861872-50-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-溴-3-苯基喹啉-2(1H)-酮
• 英文名称: 7-Bromo-3-phenylquinolin-2(1H)-one
• 英文别名: 7-bromo-3-phenyl-1H-quinolin-2-one
• CAS: 861872-50-6
• 化学式: C₁₅H₁₀BrNO
• 分子量: 300.154
• InChiKey: JQOKLXJBTAVYDO-UHFFFAOYSA-N

物化性质

• 沸点：
  471.4±45.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  7-溴-3-苯基喹啉-2(1H)-酮 在 palladium diacetate 、 N,N-二甲基甲酰胺 、 三苯基膦 氯化亚砜 、 sodium acetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 70.0~80.0 ℃ 、689.49 kPa 条件下， 生成 2-氯-3-苯基喹啉-7-羧酸甲酯
  参考文献：
  名称：

  [EN] QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS
  [FR] QUINOLÉINES ET AZA-QUINOLÉINES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR CRTH2

  摘要：

  该发明提供了一些Formula (I)中的喹啉和氮杂喹啉，以及它们的药用盐，其中E、J1、Ja、Jb、R2、R3、R22、Ra、Rb、Rc、Rd、X、Y、b、n和q如本文所定义。该发明还提供包含这些化合物的药物组合物，以及使用这些化合物治疗与CRTH2功能的不受控制或不适当刺激相关的疾病或症状的方法。

  公开号：

  WO2012087872A1
• 作为产物：
  描述：

  N-(3-bromophenyl)-α-(phenylmethylene)benzeneacetamide 在 aluminum (III) chloride 作用下， 以 氯苯 为溶剂， 反应 3.0h， 生成 7-溴-3-苯基喹啉-2(1H)-酮 、 5-bromo-3-phenyl-1H-quinolin-2-one
  参考文献：
  名称：

  [EN] QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORS
  [FR] DERIVES DE QUINOLINE ET UTILISATION DE CEUX-CI EN TANT QU'INHIBITEURS MYCOBACTERIENS

  摘要：

  本发明涉及根据一般式(Ia)或一般式(Ib)的新型取代喹啉衍生物，其药学上可接受的酸或碱盐，其季铵盐，其立体化异构体形式，其互变异构体形式和其N-氧化物形式。所述化合物可用于治疗分枝杆菌病。

  公开号：

  WO2005070430A1

文献信息

• QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS
  申请人：Boyce Christopher W.

  公开号：US20130296300A1

  公开（公告）日：2013-11-07

  The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J 1 , J a , J b , R 2 , R 3 , R 22 , R a , R b , R c , R d , X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH 2 function.

  该发明提供了公式（I）中的某些喹啉和氮杂喹啉，以及它们的药学上可接受的盐，其中E、J1、Ja、Jb、R2、R3、R22、Ra、Rb、Rc、Rd、X、Y、b、n和q的定义如本文所述。该发明还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗与CRTH2功能不受控制或不适当刺激相关的疾病或病症的方法。
• QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1912647B1

  公开（公告）日：2013-09-11
• Novel mycobacterial inhibitors
  申请人：Guillemont Emile Georges Jerome

  公开号：US20070093478A1

  公开（公告）日：2007-04-26

  The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof the tautomers forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases. In particular, compounds are claimed in which, independently from each other, R 1 is halo; p=1; R 2 is optionally substituted alkyloxy, alkyl, Ar, Het, or a radical of formula R 3 is optionally substituted Ar or Het; q=1, R 4 and R 5 each independently are alkyl; R 6 is hydrogen or a radical of formula is equal to 0 or 1 and R 7 is hydrogen or Ar. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
• Quinoline Derivatives as Antibacterial Agents
  申请人：Andries Koenraad Jozef Lodewijk Marcel

  公开号：US20080255116A1

  公开（公告）日：2008-10-16

  Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein R 1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2 or 3; R 2 is hydrogen; alkyl; hydroxy; mercapto; optionally substituted alkyloxy; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted; Ar; Het or a radical of formula R 3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is zero, 1, 2, 3 or 4; X is a direct bond or CH 2 ; R 4 and R 5 each independently are hydrogen, alkyl or benzyl; or R 4 and R 5 may be taken together including the N to which they are attached; R 6 is hydrogen or a radical of formula R 7 is hydrogen, alkyl, Ar or Het; R 8 is hydrogen or alkyl; R 9 is oxo; or R 8 and R 9 together form the radical —CH═CH—N═;
• NOVEL MYCOBACTERIAL INHIBITORS
  申请人：GUILLEMONT Jérôme Emile Georges

  公开号：US20110124870A1

  公开（公告）日：2011-05-26

  The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases. In particular, compounds are claimed in which, independently from each other, R 1 is halo; p=1; R 2 is optionally substituted alkyloxy, alkyl, Ar, Het, or a radical of formula R 3 is optionally substituted Ar or Het; q=1, R 4 and R 5 each independently are alkyl; R 6 is hydrogen or a radical of formula r is equal to 0 or 1 and R 7 is hydrogen or Ar. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.